Navigating Treatment Selection for CLL in the Relapsed/Refractory Setting
A panel of oncology experts share their general approach in navigating treatment selection for patients with R/R CLL, highlighting key factors to consider in making treatment decisions.
EP: 1.Evolving Front-line Treatment Options for CLL
EP: 2.Navigating 1L Treatment Selection with BTKis in CLL
EP: 3.Updates on BTKi Monotherapy for CLL in the Frontline Setting
EP: 4.The Role of BTKi + Obinutuzumab for 1L Treatment of CLL
EP: 5.Expert Perspectives on Fixed Duration Therapy with Venetoclax + Obinutuzumab
EP: 6.Updates on Combination Treatment Approaches with BTKi + Venetoclax
Now Viewing
EP: 7.Navigating Treatment Selection for CLL in the Relapsed/Refractory Setting
EP: 8.Expert Insights on Extended Follow-Up Data from ALPINE and ELEVATE-RR
EP: 9.Consideration Factors in Treatment Selection for BTKi Therapy in R/R CLL
EP: 10.Key Considerations in Managing Hypertension Risk with BTKis in CLL
EP: 11.Expert Perspectives on Managing Risk of Atrial Fibrillation with BTKis in CLL
EP: 12.Managing Bleeding Risk in Patients with CLL on BTKi Therapy
EP: 13.Utilizing Real-World Data for Informed Decision-Making in CLL
EP: 14.Navigating Treatment Resistance and Sequencing in CLL
EP: 15.Advancements with Novel Treatment Approaches in CLL
EP: 16.Future Perspectives and Unmet Needs in CLL
Recent Videos
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
Related Content
![We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fd5a069c33bbfe917bc7c0b1bb13d76c0a815cc44-234x234.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "We must work on clinical predictors based on the disease phenotype, we must work on the physician’s attitude, and [we must work to] stimulate the correct and timely usage of ruxolitinib.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025Podcast
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
Reprogramming the Neuroblastoma Tumor Immune Microenvironment to Enhance GPC2 CAR T-cells
September 3rd 2025Article
Researchers at the CHOP have developed a new strategy to improve the effectiveness of GPC2-directed CAR T-cell therapy in neuroblastoma by reprogramming the tumor immune microenvironment.
